HitGen Inc. Initiates Phase II Clinical Trial for HG146 in Adenoid Cystic Carcinoma
China-based HitGen Inc. (SHA: 688222) has announced the commencement of the first patient enrollment in...
Reforgene Medicine Secures Hundreds of Millions in Financing for Gene Therapy Expansion
Reforgene Medicine, a prominent gene editing therapy company headquartered in Guangzhou, has reportedly secured hundreds...
Xtalpi Inc. Partners with NCCS and Duke-NUS to Advance AI-Driven Drug Discovery
Shenzhen-based QuantumPharm Inc., trading under the name Xtalpi Inc. (HKG: 2228), has announced a strategic...
Danaher Corporation Opens Joint Office in Beijing’s Chaoyang District
US-based Danaher Corporation (NYSE: DHR), a leading science and tech services provider, has officially launched...
WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...
Hainan Free Trade Port Gets Green Light for Temporary Import of Special Medical Foods
The State Administration for Market Regulation (SAMR) in China has given its approval in principle...
GenFleet Therapeutics Submits IPO Application to HKEX, Backed by CITIC Securities
On December 27, 2024, GenFleet Therapeutics, a biopharmaceutical company based in Shanghai, submitted its application...
Overwhelming Shareholder Support for Hengrui Pharmaceuticals’ H-Share IPO
On December 26, Hengrui Pharmaceuticals (SHA: 600276) held its second extraordinary general meeting of 2024,...
Dynamiker Biotechnology Receives Approval for IPO on Beijing Stock Exchange
On December 27, 2024, the official website of the Beijing Stock Exchange announced that Dynamiker...
MicroPort Endovascular MedTech’s Castor® Branched Stent Wins China Patent Gold Award
The National Intellectual Property Administration has announced the winners of the 25th China Patent Awards,...
Daiichi Sankyo and AstraZeneca Withdraw EU Application for Datopotamab Deruxtecan in Lung Cancer
Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced the voluntary...
AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions
UK major AstraZeneca’s (AZ, NASDAQ: AZN) China unit has announced a new round of structural...
Beijing Releases List of Novel Drugs and Technologies Exempt from CHS-DRG Payment Scheme
The Beijing Municipal Medical Insurance Bureau has released the list of the first batch of...
Johnson & Johnson Secures Licensing Deal with Kaken Pharmaceutical for STAT6 Program
US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced an exclusive licensing agreement with...
Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach
China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to...
Auzone Submits NDA for Oral Edaravone TTYP01 to Treat ALS
Auzone Biological Technology has announced the submission of a New Drug Application (NDA) for its...
Pediatrix Therapeutics’ Neffy NDA Accepted by NMPA for Allergy Treatment
China-based Pediatrix Therapeutics has announced that the New Drug Application (NDA) for its neffy (epinephrine...
Immunochina Pharmaceuticals and Cell Store Partner to Advance Cell Therapy Commercialization in China
Beijing-based firms Immunochina Pharmaceuticals and Cell Store have announced a strategic partnership aimed at bolstering...
Hinova Pharmaceuticals Enrolls First Patient in Phase II Study for HP518 in mCRPC
China-based biopharma Hinova Pharmaceuticals has announced the enrollment of the first patient in an open,...
Xbiome Partners with ZoHealth to Advance Microbiome Drug Development and Precision Nutrition
China-based Xbiome, an AI-driven microbiome drug development company, has announced a strategic alliance with Australia-headquartered...